Harrison Phillips

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

The Viridian Cannabis Deal Tracker is an information service that monitors capital raise and M&A activity in the legal cannabis industry. Analyzing within 12 key industry sectors, the Viridian Cannabis Deal Tracker provides cannabis companies, investors, and acquirers with the data, trends, and...

Macquarie's Caroline Levy provided clients with an outline of some of the key trends a panel of experts sees ahead for the alcohol market.  The sell-side firm recently hosted a panel of beer and cannabis experts including beer-guru Harry Schuhmacher, founder of Beer Business Daily;...

Macquarie Research recently hosted an event featuring beer guru Harry Schuhmacher, founder of Beer Business Daily; Emily Pennington, editor of Wine & Spirits Daily; and Harrison Phillips, cannabis industry financial advisor. Among the topics the panel discussed: the potential for cannabis...

This week, Tilray and Sproutly Canada went public, Sunniva announced plans to spin off its Canadian assets, Zynerba Pharmaceuticals posted positive data for its Phase 2 trial for ZYN002 in Fragile X syndrome, and Zogenix released positive top-line results from its second pivotal Phase 3 study...

A shortened week brought less cannabis news than usual, providing the people in the industry with a chance to exhale and look back at the convoluted weeks leading up to the Fourth of July holiday.  We did witness some relevant action. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) reported...

Cannabis investors can't afford to miss the Benzinga Cannabis Capital Conference, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited—get your tickets before they sell out. Ahead of the...

Almost every week, an American or Canadian cannabis company announces a large overseas investment. And it's no longer just Germany, Israel and Australia that are piquing investors’ interest. Emerging markets like Jamaica are also turning heads. The largest investment opportunities might...

Shares of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) were halted Thursday, ahead of a Food and Drug Administration vote on the company's cannabis-derived drug Epidiolex. Trading resumed after the FDA advisory panel voted unanimously in favor of approving the medicine for the treatment of two...

January was a great month for the cannabis industry, despite Attorney General Jeff Sessions’ decision to rescind the Cole Memo, an Obama-era memorandum that essentially protected state-legal cannabis businesses from federal prosecution. Marijuana companies received more than $1.2 billion in...